Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup

AM Al-Rubaish; FA Al-Muhanna; AM Alshehri; AA Alsulaiman; MM Alabdulali; F Alkhamis; AS Alamri; RA Alali; MS Akhtar; C Cyrus; DMF Claassens; FW Asselbergs; AK Al-Ali

doi:10.1515/dmdi-2021-0104

Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup

AM Al-Rubaish
, FA Al-Muhanna
, AM Alshehri
, AA Alsulaiman
, MM Alabdulali
, F Alkhamis
, AS Alamri
, RA Alali
, MS Akhtar
, C Cyrus
, DMF Claassens
, FW Asselbergs
, AK Al-Ali

UMCU

Research output: Contribution to journal › Article › Academic › peer-review

4 Downloads (Pure)

Original language	Undefined/Unknown
Journal	Drug Metabolism and Personalized Therapy
DOIs	https://doi.org/10.1515/dmdi-2021-0104
Publication status	Published - 8 Jul 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1515/dmdi-2021-0104

Prevalence-of-cyp2c192-carriers-in-saudi-ischemic-stroke-patients-and-the-suitability-of-using-genotyping-to-guide-anti.pdfFinal published version, 202 KBLicence: Taverne

Cite this

Al-Rubaish, AM., Al-Muhanna, FA., Alshehri, AM., Alsulaiman, AA., Alabdulali, MM., Alkhamis, F., Alamri, AS., Alali, RA., Akhtar, MS., Cyrus, C., Claassens, DMF., Asselbergs, FW., & Al-Ali, AK. (2021). Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup. Drug Metabolism and Personalized Therapy. https://doi.org/10.1515/dmdi-2021-0104

@article{2c9c467010e74d5196c4773d8b6d255b,

title = "Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup",

author = "AM Al-Rubaish and FA Al-Muhanna and AM Alshehri and AA Alsulaiman and MM Alabdulali and F Alkhamis and AS Alamri and RA Alali and MS Akhtar and C Cyrus and DMF Claassens and FW Asselbergs and AK Al-Ali",

year = "2021",

month = jul,

day = "8",

doi = "10.1515/dmdi-2021-0104",

language = "Undefined/Unknown",

journal = "Drug Metabolism and Personalized Therapy",

issn = "2363-8907",

publisher = "Walter de Gruyter GmbH",

}

Al-Rubaish, AM, Al-Muhanna, FA, Alshehri, AM, Alsulaiman, AA, Alabdulali, MM, Alkhamis, F, Alamri, AS, Alali, RA, Akhtar, MS, Cyrus, C, Claassens, DMF, Asselbergs, FW & Al-Ali, AK 2021, 'Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup', Drug Metabolism and Personalized Therapy. https://doi.org/10.1515/dmdi-2021-0104

TY - JOUR

T1 - Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup

AU - Al-Rubaish, AM

AU - Al-Muhanna, FA

AU - Alshehri, AM

AU - Alsulaiman, AA

AU - Alabdulali, MM

AU - Alkhamis, F

AU - Alamri, AS

AU - Alali, RA

AU - Akhtar, MS

AU - Cyrus, C

AU - Claassens, DMF

AU - Asselbergs, FW

AU - Al-Ali, AK

PY - 2021/7/8

Y1 - 2021/7/8

U2 - 10.1515/dmdi-2021-0104

DO - 10.1515/dmdi-2021-0104

M3 - Article

C2 - 34237806

SN - 2363-8907

JO - Drug Metabolism and Personalized Therapy

JF - Drug Metabolism and Personalized Therapy

ER -